Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.

PubWeight™: 5.12‹?› | Rank: Top 1%

🔗 View Article (PMC 4132650)

Published in Brain on July 02, 2014

Authors

Niccolò E Mencacci1, Ioannis U Isaias2, Martin M Reich3, Christos Ganos4, Vincent Plagnol5, James M Polke6, Jose Bras7, Joshua Hersheson7, Maria Stamelou8, Alan M Pittman9, Alastair J Noyce9, Kin Y Mok7, Thomas Opladen10, Erdmute Kunstmann11, Sybille Hodecker12, Alexander Münchau13, Jens Volkmann14, Samuel Samnick15, Katie Sidle7, Tina Nanji6, Mary G Sweeney6, Henry Houlden7, Amit Batla16, Anna L Zecchinelli14, Gianni Pezzoli14, Giorgio Marotta17, Andrew Lees18, Paulo Alegria19, Paul Krack20, Florence Cormier-Dequaire21, Suzanne Lesage22, Alexis Brice23, Peter Heutink24, Thomas Gasser24, Steven J Lubbe25, Huw R Morris25, Pille Taba26, Sulev Koks27, Elisa Majounie28, J Raphael Gibbs28, Andrew Singleton28, John Hardy9, Stephan Klebe3, Kailash P Bhatia29, Nicholas W Wood30, International Parkinson’s Disease Genomics Consortium and UCL-exomes consortium

Author Affiliations

1: 1 Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK2 IRCCS Istituto Auxologico Italiano, Department of Neurology and Laboratory of Neuroscience - Department of Pathophysiology and Transplantation, "Dino Ferrari" Centre, Università degli Studi di Milano, 20149 Milan, Italy.
2: 3 Department of Neurology, University Hospital, 97080 Würzburg, Germany4 Parkinson Institute, Istituti Clinici di Perfezionamento, 20126 Milan, Italy.
3: 3 Department of Neurology, University Hospital, 97080 Würzburg, Germany.
4: 5 Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London WC1N 3BG, UK6 Department of Neurology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany7 Department of Paediatric and Adult Movement Disorders and Neuropsychiatry, Institute of Neurogenetics, University of Lübeck, 23538 Lübeck, Germany.
5: 8 UCL Genetics Institute, London WC1E 6BT, UK.
6: 9 Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK.
7: 1 Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK.
8: 5 Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London WC1N 3BG, UK10 Neurology Clinic, Attiko Hospital, University of Athens, 126 42 Haidari, Athens, Greece11 Neurology Clinic, Philipps University, 35032 Marburg, Germany.
9: 1 Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK12 Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London WC1N 3BG, UK.
10: 13 Division of Inborn Errors of Metabolism, University Children's Hospital Heidelberg, 69120 Heidelberg, Germany.
11: 14 Institut of Human Genetics, Julius-Maximilian-University, 97070 Würzburg, Germany.
12: 6 Department of Neurology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany.
13: 7 Department of Paediatric and Adult Movement Disorders and Neuropsychiatry, Institute of Neurogenetics, University of Lübeck, 23538 Lübeck, Germany.
14: 4 Parkinson Institute, Istituti Clinici di Perfezionamento, 20126 Milan, Italy.
15: 15 Department of Nuclear Medicine, University Hospital, 97080 Würzburg, Germany.
16: 5 Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London WC1N 3BG, UK.
17: 16 Department of Nuclear Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy.
18: 12 Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London WC1N 3BG, UK.
19: 17 Serviço de Neurologia, Hospital Beatriz Ângelo, 2674-514 Loures, Portugal.
20: 18 Movement Disorder Unit, CHU Grenoble, Joseph Fourier University, and INSERM U836, Grenoble Institute Neuroscience, F-38043 Grenoble, France.
21: 19 Université Pierre et Marie Curie-Paris6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UMR-S975; Inserm, U975, Cnrs, UMR 7225, Paris, France20 Centre d'Investigation Clinique (CIC-9503), Département de Neurologie, Hôpital Pitié-Salpétriêre, AP-HP, Paris, France.
22: 19 Université Pierre et Marie Curie-Paris6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UMR-S975; Inserm, U975, Cnrs, UMR 7225, Paris, France.
23: 19 Université Pierre et Marie Curie-Paris6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UMR-S975; Inserm, U975, Cnrs, UMR 7225, Paris, France21 Département de Génétique et Cytogénétique, Pitié-Salpêtrière hospital, 75013 Paris, France.
24: 22 DZNE-Deutsches Zentrum für Neurodegenerative Erkrankungen (German Centre for Neurodegenerative Diseases), Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany.
25: 23 Department of Clinical Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK.
26: 24 Department of Neurology and Neurosurgery, University of Tartu, 50090 Tartu, Estonia.
27: 25 Department of Pathophysiology, Centre of Excellence for Translational Medicine, University of Tartu, 50411 Tartu, Estonia.
28: 26 Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD 20892, USA.
29: 5 Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London WC1N 3BG, UK n.wood@ucl.ac.uk k.bhatia@ucl.ac.uk.
30: 1 Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK n.wood@ucl.ac.uk k.bhatia@ucl.ac.uk.

Articles citing this

Dopa-responsive dystonia--clinical and genetic heterogeneity. Nat Rev Neurol (2015) 1.10

Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease. Hum Mol Genet (2015) 0.82

The Concept of Prodromal Parkinson's Disease. J Parkinsons Dis (2015) 0.81

Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain (2014) 0.79

Parkinsonism in GTP cyclohydrolase 1 mutation carriers. Brain (2014) 0.79

A new knock-in mouse model of l-DOPA-responsive dystonia. Brain (2015) 0.79

Parkinsonism in GTP cyclohydrolase 1-deficient DOPA-responsive dystonia. Brain (2014) 0.79

Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain (2014) 0.78

Reduced Number of Pigmented Neurons in the Substantia Nigra of Dystonia Patients? Findings from Extensive Neuropathologic, Immunohistochemistry, and Quantitative Analyses. Tremor Other Hyperkinet Mov (N Y) (2015) 0.78

Novel GCH1 variant in Dopa-responsive dystonia and Parkinson's disease. Parkinsonism Relat Disord (2015) 0.77

Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurol (2016) 0.77

Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson's Disease. Parkinsons Dis (2016) 0.76

GTP cyclohydrolase 1 mutations and Parkinson's disease: new insights beyond DOPA-responsive dystonia. Mov Disord (2015) 0.75

Reply: Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain (2014) 0.75

Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease. Neurobiol Aging (2016) 0.75

Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect? Front Aging Neurosci (2017) 0.75

Unmet Needs in Dystonia: Genetics and Molecular Biology-How Many Dystonias? Front Neurol (2017) 0.75

Parkinsonism in Association with Dihydropteridine Reductase Deficiency. Case Rep Neurol (2017) 0.75

Hereditary dystonia and parkinsonism: two sides of the same coin? Brain (2014) 0.75

Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity. Neurobiol Aging (2016) 0.75

Beyond the Classic Segawa Disease, GCH1-Associated Neurodegenerative Parkinsonism: Practical Considerations for Physicians. J Mov Disord (2017) 0.75

A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain (2017) 0.75

Articles cited by this

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res (2010) 43.51

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67

Parkinson's disease. Lancet (2009) 6.60

A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet (2011) 3.16

Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology (2011) 3.10

New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology (1991) 1.57

The genetics and neuropathology of Parkinson's disease. Acta Neuropathol (2012) 1.56

Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry (2009) 1.46

Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain (2009) 1.44

Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity. Hum Mol Genet (1996) 1.38

Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain (2000) 1.36

High mutation rate in dopa-responsive dystonia: detection with comprehensive GCHI screening. Neurology (2005) 1.34

The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol (2011) 1.30

Imaging essential tremor. Mov Disord (2010) 1.27

Dopa-responsive dystonia: a clinical and molecular genetic study. Ann Neurol (1998) 1.25

Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain (2011) 1.20

Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology (1998) 1.19

Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia. Neurology (1999) 1.16

The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov Disord (2012) 1.13

Approach to the diagnosis of neurotransmitter diseases exemplified by the differential diagnosis of childhood-onset dystonia. Ann Neurol (2003) 1.12

Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann Neurol (1993) 1.06

Low frequency of Parkin, Tyrosine Hydroxylase, and GTP Cyclohydrolase I gene mutations in a Danish population of early-onset Parkinson's Disease. Eur J Neurol (2006) 1.04

Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive myoclonus-dystonia syndrome. Neurology (2002) 1.04

Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol (1998) 1.00

Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia. Ann Neurol (1992) 0.99

Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology (1990) 0.99

Dopamine protects neurons against glutamate-induced excitotoxicity. Cell Death Dis (2013) 0.98

Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J (2003) 0.97

Arg(184)His mutant GTP cyclohydrolase I, causing recessive hyperphenylalaninemia, is responsible for dopa-responsive dystonia with parkinsonism: a case report. Mov Disord (2004) 0.97

Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis. Adv Neurol (1993) 0.96

Dopa-responsive dystonia and early-onset Parkinson's disease in a patient with GTP cyclohydrolase I deficiency? Mov Disord (2006) 0.96

Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models. Synapse (1999) 0.96

Are Dopa-responsive dystonia and Parkinson's disease related disorders? A case report. Parkinsonism Relat Disord (2011) 0.94

Paroxysmal exercise-induced dystonia as a presenting feature of young-onset Parkinson's disease. Mov Disord (2003) 0.94

Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging (2012) 0.93

Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord (2001) 0.92

Phenylalanine loading as a diagnostic test for DRD: interpreting the utility of the test. Mol Genet Metab (2004) 0.89

GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs. J Neurol Neurosurg Psychiatry (1997) 0.88

Expanding the clinical phenotype of DYT5 mutations: is multiple system atrophy a possible one? Neurology (2013) 0.88

Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Mov Disord (2010) 0.88

Biochemical and fluorodopa positron emission tomographic findings in an asymptomatic carrier of the gene for dopa-responsive dystonia. Ann Neurol (1994) 0.88

The phenylalanine loading test in the differential diagnosis of dystonia. Neurology (2003) 0.87

GTP-cyclohydrolase I gene mutations in patients with autosomal dominant and recessive GTP-CH1 deficiency: identification and functional characterization of four novel mutations. J Inherit Metab Dis (2004) 0.87

Dopa-responsive dystonia is induced by a dominant-negative mechanism. Ann Neurol (2000) 0.86

Is phenotypic variation of hereditary progressive dystonia with marked diurnal fluctuation/dopa-responsive dystonia (HPD/DRD) caused by the difference of the locus of mutation on the GTP cyclohydrolase 1 (GCH-1) gene? Adv Neurol (2004) 0.86

Novel GCH-1 mutations and unusual long-lasting dyskinesias in Korean families with dopa-responsive dystonia. Parkinsonism Relat Disord (2013) 0.85

Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia. Ann Neurol (2002) 0.85

Dopa-responsive dystonia: some pieces of the puzzle are still missing. Neurology (1998) 0.85

The GTP-cyclohydrolase I gene in atypical parkinsonian patients: a clinico-genetic study. J Neurol Sci (1996) 0.85

A case of parkinsonism and dopa-induced severe dyskinesia associated with novel mutation in the GTP cyclohydrolase I gene. Parkinsonism Relat Disord (2011) 0.85

Urinary neopterin and phenylalanine loading test as tools for the biochemical diagnosis of segawa disease. JIMD Rep (2012) 0.84

Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia. Neurology (1993) 0.84

Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations. Mov Disord (2004) 0.84

GCH1 in early-onset Parkinson's disease. Mov Disord (2009) 0.83